Rep. DeLauro: An Accounting for American Taxpayers on Their Investment in Remdesivir Treatment for COVID-19
May 01, 2020
May 01, 2020
WASHINGTON, May 1 -- Rep. Rosa L. DeLauro, D-Connecticut, issued the following news release:
Amid announcements concerning preliminary clinical trial data on remdesivir and anticipated emergency use authorization from the FDA, U.S. Representative Lloyd Doggett (D-TX), Chair of the House Ways and Means Health Subcommittee, and Rep. Rosa DeLauro (D-CT), Chair of the Labor, Health and Human Services, and Education Appropriations Subcommittee, urge Secretary Azar to release information . . .
Amid announcements concerning preliminary clinical trial data on remdesivir and anticipated emergency use authorization from the FDA, U.S. Representative Lloyd Doggett (D-TX), Chair of the House Ways and Means Health Subcommittee, and Rep. Rosa DeLauro (D-CT), Chair of the Labor, Health and Human Services, and Education Appropriations Subcommittee, urge Secretary Azar to release information . . .